Rhinoconjunctivitis is a combination of rhinitis and conjunctivitis and is one of the most common allergic reactions across the globe. It is an inflammatory disorder which affects nasal and conjunctival mucosa and is induced as a result of hypersensitive immune response. Rhinoconjunctivitis causes symptoms of allergic rhinitis such as sneezing, watery mucus, itchy nose, and nasal congestion, as well as conjunctivitis which include burning sensation, tears and redness of eyes. These symptoms may also be accompanied by systemic symptoms such as poor sleep, irritability and fatigue. Allergic rhinoconjunctivitis is often mistaken with common cold and a person may realize this only after carrying out considerable allergy diagnostics. Various allergens are known to cause rhinoconjunctivitis including pollen grains, dust and dust mites, animal skin or dander, perfumes, smoke, hair and several others. Allergic rhinitis is one of the most common allergic reactions in U.S. According to National Institute for Health Research, more than 10 million individuals in the U.K. suffer from allergic rhinitis. The institute also explains that the over 90% of the individuals with allergic rhinitis frequently suffer from ocular symptoms. An article published in Journal of Allergy and Therapy mentions that allergic rhinitis is one of the most common reasons for hospital visits due to allergies. Other publications also report that majority of the patients with asthma also suffer from rhinitis, and over 20% of patients with rhinoconjunctivitis also have concomitant asthma.
A broad spectrum of treatment is available for treatment of rhinoconjunctivitis. The treatment for allergic conjunctivitis includes both topical as well as systemic interventions such decongestants, mast-cell stabilizers, antihistamines, nonsteroidal anti-inflammatory drugs, and intranasal corticosteroids. In case of occasional symptoms, Claritin (loratadine), Reactine (cetirizine), Aerius (desloratadine), Allegra (fexofenadine) are prescribed. While if the symptoms are more frequent, intra-nasal corticosteroids are prescribed which include Avamys, Flonase, Nasacort, Nasonex, Omnaris, Rhinocort.
Article published in World Allergy Organizations Journal in 2013 suggests that no accurate data is available for studying the prevalence and its changing trends. This has hampered the research and development activities. The study also found that the prevalence of non food allergies is also increasing rapidly in Asia. Allergic asthma is also a rising concern for many countries. More than 5 million people in the U.K. suffer from asthma. A report published by European Environment and Health Information System, considerable increase in prevalence was observed for rhinoconjunctivitis in Poland, Romania and the Russia Federation for rhinoconjunctivitis. This increasing prevalence is a major factor driving the global rhinoconjunctivitis market. Consistent research and development, and growing awareness about allergies would also support the growth, especially in developing countries. Prevalence of allergic rhinitis has increased considerably in adults as well as children. Consumption of food that has been preserved extensively in refrigerators, industrialization and air pollution are also responsible for the increased prevalence according to a study published in Allergy, Asthma & Immunology Research Journal. Similar conditions prevail in India, Korea, Singapore and other Asian countries.
Various pharmaceutical companies and research institutes are conducting research for the discovery for better treatment of the allergy. Merck Sharp & Dohme Corp. is currently conducting phase III clinical trials for SCH 697243 a biological drug, and another candidate MK-8237 is under phase I trials. BioTech Tools S.A. is also developing gpASIT+TM as a potential treatment for rhinoconjunctivitis. The study is currently under phase II clinical trials. Such consistent research activities will add more products in the market and expand its scope. Some of the key players in the market include Johnson & Johnson Inc., Merck & Co., Inc. GlaxoSmithKline, and Sanofi.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.